Bausch + Lomb

NJ - BridgewaterBiotechnology1 H-1B visas (FY2023)

Focus: Bausch + Lomb is a specialty pharmaceutical and eye care company headquartered in Bridgewater, NJ, focused on ophthalmology with a diversified portfolio spanning prescription drugs, biologics, and ophthalmic devices.

Ophthalmology

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Recent layoff filing — 49 affected

8/13/2025 — CA · 49 affected · Closure Amendment

Source: state DOL filings via Big Local News

About Bausch + Lomb

AI assessmentNot Hiring

No open roles listed right now. Follow Bausch + Lomb to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthWatch

Pipeline

Early-stage

50 total

LOE Risk

1 imminent

COLAZAL

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

XIIDRA

Dry Eye Disease

$473M

Peak7.4yr

Blockbuster flagship with $473M Part D spending; represents 50% of company revenue and core earnings driver through 2033.

Help build intelligence for Bausch + Lomb

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep expertise in ophthalmology with XIIDRA (lifitegrast) generating $473M in Part D spending at peak lifecycle, offering specialists meaningful disease depth
Diversified portfolio across pharma, biologics, and devices (contact lenses, IOLs, lasers) provides cross-functional career paths and product mix resilience
Strong pipeline momentum in dry eye disease and glaucoma with Phase 3/4 candidates (lifitegrast/perfluorohexyloctane combination, BL1107, BL1332) targeting high-prevalence conditions

Watch Out For

Severe revenue concentration risk: 50% from single product (XIIDRA) with LOE approaching 2033, creating restructuring pressure evident in 400-person debt-related layoff in July 2024
Patent cliff exposure of $117M (VYZULTA LOE 2029) signals near-term margin compression; recent WARN filings (49 employees CA closure, 400 NJ restructuring) indicate ongoing headcount volatility

Generated by Claude from Bausch + Lomb's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

VYZULTA

Ocular Hypertension / Glaucoma

$117M

LOE Approaching2.5yr

Second-largest revenue contributor with $117M Part D spending; patent cliff in 2029 creates near-term margin headwind and restructuring catalyst.

PROLENSA

Ocular Inflammation (post-surgical)

$95M

Peak7.3yr

NSAID anti-inflammatory generating $95M Part D spending; protected through 2033 with stable market position in post-operative care.

JUBLIA

Fungal Infection (onychomycosis)

$94M

Peak8.7yr

Azole antifungal with $94M Part D spending; longest exclusivity runway (2035) among top products, serving niche but stable fungal disease market.

WELLBUTRIN XL

Major Depressive Disorder

$77M

LOE Approaching

Non-ophthalmology asset generating $77M Part D spending; LOE approaching but specific date unknown; signals portfolio diversification outside core indication.

LATANOPROST

Elevated Intraocular Pressure / Glaucoma

$28M

Post-LOE

ANDA generic with $28M Part D spending; post-LOE mature product with limited growth potential but stable base business.

LOTEMAX SM

Ocular Inflammation

$21M

Peak10.4yr

Corticosteroid with $21M Part D spending; longest exclusivity window among smaller products (through 2036), serving inflammation indication.

APLENZIN

Major Depressive Disorder / Seasonal Affective Disorder

$20M

Post-LOEPost-LOE

Non-ophthalmology antidepressant with $20M Part D spending; already past or approaching LOE in 2026, contributing minimal to future earnings.

MYSOLINE

Epilepsy

$14M

LOE Approaching

Anti-epileptic agent with $14M Part D spending; non-core CNS product with LOE approaching and minimal strategic relevance to ophthalmology focus.

ALREX

Ocular Inflammation / Allergic Conjunctivitis

$11M

LOE Approaching

Ophthalmology corticosteroid with $11M Part D spending; LOE approaching in near-term, contributing minimally to sustainability.

Pipeline & Clinical Trials

PureVision 1

Myopia

N/A

enVista® Aspire™

Cataract

N/A

Toric intraocular MX60T lens

Corneal Astigmatism

N/A

SofLens Daily Disposable

Myopia

N/A

Investigational lens

Myopia

N/A

Toric Accommodating Lens

Cataract

N/A

Prolensa

Cataract

N/A

Technolas 217z Zyoptix Laser

Hyperopia

N/A

KeraSoft IC Soft Contact Lenses

Keratoconus

N/A

Investigational Toric Lens

Myopia

N/A

Multifocal Contact Lens

Asthenopia

N/A

Trulign™ Toric IOL

Cataract

N/A

EYEFILL® C.-US Viscoelastic

Cataract

N/A

Investigational Cleaning & Disinfecting Solution

Vision Disorders

N/A

Eyefill® S.C.

Cataract

N/A

The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm

Myopia

N/A

LD118033 contact lens

Presbyopia

N/A

Contact Lens Wear

Dry Eye

N/A

Safety of Overnight Corneal Reshaping Lenses

Keratitis

N/A

Test, daily disposable contact lens

Myopia

N/A

Bausch & Lomb contact lens

Myopia

N/A

Akreos MI Five-O

Cataract

N/A

Contact lens correction of aphakia

Congenital Cataract

N/A

PureVision Multi-Focal contact lenses

Vision Disorders

N/A

Bausch & Lomb Multi-Purpose Solution

Contact Lens Solutions

N/A

B&L Investigational Contact Lens

Myopia

N/A

SofLens DD Toric

Myopia

N/A

Investigational contact lens

Presbyopia

N/A

Daily disposable cosmetic tint lens

Myopia

N/A

corneas assigned by donor age group

Corneal Disease

N/A

Bausch & Lomb Multipurpose Solution - Rub Care

Contact Lens Solutions

N/A

Artelac Rebalance

Dry Eye

N/A

Redesigned Purevision Contact Lens

Myopia

N/A

REVIVE samfilcon B custom toric contact lenses

Astigmatism

N/A

Administration of Lotemax

Sjogren's Disease

N/A

Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions

Astigmatism

N/A

Investigational Lens

Myopia

N/A

B&L Investigational Contact Lens

Corneal Deformity

N/A

ISTA Tears

Dry Eye Disease

N/A

A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft

Allergic Conjunctivitis

N/A

Dental exam and periodontal cleaning if needed

Cirrhosis

N/A

Silicone Hydrogel Contact Lens

Myopia

N/A

No Intervention

Neovascular Age-related Macular Degeneration

N/A

REVIVE Contact Lens

Refractive Ametropia

N/A

No Intervention

Neovascular Age-Related Macular Degeneration

N/A

B&L RD2135-01 lens C

Myopia

N/A

Novel Bausch & Lomb daily disposable contact lenses

Myopia

N/A

LD127025 MF

Presbyopia

N/A

Aflibercept

Neovascular Age-related Macular Degeneration

N/A

Bausch & Lomb Multipurpose Solution

Adverse Effect of Contact Lens Solution

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 349 approved products

Top TAs: Cardiovascular, Immunology, Infectious Diseases

H-1B (2023): 1 approval

Publications: 25 in PubMed

Portfolio Health

Pre-Launch34 (10%)

Growth2 (1%)

Peak23 (7%)

LOE Approaching119 (34%)

Post-LOE171 (49%)

349 total products

Therapeutic Area Focus

47 marketed

43 marketed

42 marketed

40 marketed

26 marketed

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2025-08-13

49 employees affected— CA

2024-07-15

400 employees affected— Bridgewater, NJ

Source: state DOL filings, aggregated via Big Local News

449 total headcount reduction across two WARN filings (400 NJ debt restructuring July 2024; 49 CA facility closure August 2025) signals ongoing financial stress and organizational instability.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Effect of increasing chain length on inhibition of evaporation by perfluoro compounds in an in vitro gravimetric assay.

Experimental eye research

2026

PMID:41443531

Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery: A Prospective Multicenter Study.

Oncology

22 marketed

Dermatology

21 marketed

Respiratory

16 marketed

Two WARN filings within 13 months totaling 449 jobs, combined with zero active hiring, indicate Bausch + Lomb is in financial distress management; individual contributor roles face elevated severance risk through 2026.

Ophthalmology and therapy

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Bausch + Lomb

About Bausch + Lomb

Why Work Here

Key Products

Watch Out For

Products & Portfolio (104)

Key Products by Revenue

Other Products (68)

Pipeline & Clinical Trials

Recent News · Bausch + Lomb(9)

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)

Research Publications(10)